Bachem stock holds gains as peptide demand supports revenue growth

Bachem stock reflects sustained demand for peptide and oligonucleotide APIs, with recent annual figures showing double digit revenue growth and an expanding order backlog.

Bachem stock is tied closely to the performance of Bachem Holding AG (ISIN CH0012530207), a Swiss specialist in peptide and oligonucleotide active pharmaceutical ingredients for the global biotech and pharmaceutical industry. As a pure play on complex APIs, Bachem's share price tends to react to shifts in revenue growth, margins, and capacity expansion rather than short term macro headlines. In the most recent reported full year, Bachem generated around CHF 500 million in revenue, pointing to a business that has scaled meaningfully from the lower hundreds of millions a few years ago. For investors, the key signal is that peptide demand in areas like oncology and metabolic disease continues to underpin the companys order book and utilization rates.

Revenue up double digits

Revenue is a central metric for assessing Bachem stock because the company operates in a niche but fast growing segment of the pharmaceutical supply chain. In its latest full year, Bachem reported revenues of roughly CHF 500 million, compared with about CHF 400 million in the prior year period, implying growth of around 25%. This step up in revenue, on a base that had already grown in previous years, indicates that the company is capturing a larger share of peptide and oligonucleotide outsourcing trends as more biopharmaceutical companies move complex synthesis to specialized suppliers.

Beyond the headline revenue number, Bachem also reports operating profitability metrics that help frame the resilience of its business model. With EBITDA margin estimated in the mid to high twenties percent range, Bachem converts a substantial portion of its top line into operating cash flow that can be used for capacity expansion, process automation, and selective investments in new technologies. The combination of approximately CHF 500 million in sales and an EBITDA margin above 25% implies EBITDA on the order of CHF 125 million or more in the latest year, enough to fund expansion projects without overreliance on external capital.

Order backlog and capacity expansion

For Bachem stock, another important fundamental metric is the order backlog, which reflects commitments from pharmaceutical and biotech clients over several years. Recent figures from the company context point to a backlog of several hundred million Swiss francs, providing multi year visibility into revenue and supporting decisions to invest in new manufacturing sites and equipment. When an order backlog expands faster than current year revenue, as has been the case for Bachem in recent reporting cycles, it signals that future sales could outpace historical levels once new capacity is fully online.

Capacity expansion is critical because peptide and oligonucleotide synthesis is capital intensive and requires significant investment in reactors, purification systems, and quality control infrastructure. Bachem has been investing hundreds of millions of Swiss francs over several years into new facilities in Switzerland, Europe, and North America to meet demand from both large pharmaceutical companies and emerging biotech firms. These capital expenditures, while weighing on free cash flow in the short term, are designed to support revenue growth above CHF 500 million in coming periods and to maintain or improve the companys EBITDA margin once volume ramps at new sites.

Peptide APIs drive growth

On the product side, Bachem is best known for its portfolio of peptide APIs, which are used by pharmaceutical companies in therapies ranging from cancer treatments to metabolic and endocrine disorders. Peptides are short chains of amino acids that can be tailored to interact with specific targets in the body, and their complexity makes high quality manufacturing a specialized task. Bachem has built expertise over decades in solid phase and liquid phase peptide synthesis, purification, and analytical characterization, enabling it to serve both commercial scale products and clinical trial supplies.

The company also has an expanding presence in oligonucleotide APIs, which are short strands of nucleic acids used in antisense and RNA based therapies. This segment complements its peptide business and positions Bachem to participate in a broader range of innovative modalities being developed in the biotech sector. As more RNA and DNA targeted drugs progress through clinical trials and into commercialization, demand for oligonucleotide APIs is likely to provide an additional layer of growth on top of peptide revenues. For Bachem, the combined opportunity in peptides and oligonucleotides supports the case for sustained capital investment and could help diversify revenue beyond any single therapeutic area.

Stock valuation and market metrics

In equity market terms, Bachem stock is listed on the SIX Swiss Exchange, where it trades in Swiss francs and is followed by both domestic and international investors interested in life sciences suppliers. At a share price level in the low to mid triple digit CHF range, the implied market capitalization for Bachem stands in the low to mid single digit billions of Swiss francs, reflecting expectations for continued growth and profitability. Price to earnings and enterprise value to EBITDA multiples for the stock have at times traded above the broader market, thanks to the companys positioning in structurally growing end markets and its track record of revenue expansion from roughly CHF 400 million to about CHF 500 million over a year.

Volatility in Bachem stock often comes from changes in guidance or updates on large scale capacity projects, rather than from short term macroeconomic swings. When the company confirms that demand is strong enough to support full utilization of new manufacturing lines, investors tend to look beyond near term capital expenditure peaks and focus on normalized profitability and cash generation. Conversely, if projects are delayed or customers adjust their ordering patterns, the stock can react as earnings trajectories are recalibrated. For long term holders, the key consideration is whether peptide and oligonucleotide outsourcing remains on an upward path and whether Bachem maintains its technological and quality advantages.

Representative product line

Among its many offerings, Bachem markets a range of catalog peptides and custom manufactured APIs that support both research and commercial use. These products include amino acid derivatives, peptide fragments, and fully formulated active ingredients tailored to individual client specifications. The catalog segment provides recurring revenue from laboratories and smaller-scale users, while large custom projects for branded medicines can generate substantial multi year revenue streams. By balancing standardized catalog products with bespoke manufacturing, Bachem can smooth revenue and margin volatility while remaining closely tied to innovation in biotechnology.

Share price context

For investors monitoring Bachem stock, the current share price on the SIX Swiss Exchange in Swiss francs sits in a range that implies a market capitalization in the low to mid single digit billions of CHF. This valuation embeds expectations that revenue, which has climbed from approximately CHF 400 million to about CHF 500 million in the most recent full year, will continue to grow as peptide and oligonucleotide demand stays firm. While day to day price moves can be influenced by sentiment and sector flows, the fundamental drivers remain capacity utilization, order backlog development, and margin resilience as new manufacturing sites ramp.

Bachem stock facts

• Company: Bachem Holding AG
• ISIN: CH0012530207
• Ticker: SIX: BACN
• Trading venue: SIX Swiss Exchange
• Market capitalization: Low to mid single digit billions CHF (recent period)
• Sector / Industry: Health Care / Pharmaceuticals and Biotechnology suppliers
• Index membership: Swiss mid cap and sector related indices